Clinical trial
Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence…
NCT00441727 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00441727 |
|---|---|
| Title | Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA) |
| Official title | A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA) |
| Acronym | Oberon |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastric Ulcer, Duodenal Ulcer |
| Intervention type | Drug |
| Interventions | Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo |
| Enrollment | 2,426 |
| Start date | Feb 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Mar 1, 2007 |
| Last update posted | Jul 16, 2012 |
| Countries | Argentina, Australia, Bulgaria, Canada, Czechia, Finland, Germany, Indonesia, Mexico, Norway, Philippines, Poland and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: